The potential of a protease activation mutant of a highly pathogenic avian influenza virus for a pandemic live vaccine
- 13 February 2008
- Vol. 26 (7) , 956-965
- https://doi.org/10.1016/j.vaccine.2007.11.052
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Protection of Mice against Lethal Infection with Highly Pathogenic H7N7 Influenza A Virus by Using a Recombinant Low-Pathogenicity Vaccine StrainJournal of Virology, 2005
- Cross‐Reactivity to Highly Pathogenic Avian Influenza H5N1 Viruses after Vaccination with Nonadjuvanted and MF59‐Adjuvanted Influenza A/Duck/Singapore/97 (H5N3) Vaccine: A Potential Priming StrategyThe Journal of Infectious Diseases, 2005
- A protective immune response in mice to viral components other than hemagglutinin in a live influenza A virus vaccine modelVaccine, 2004
- Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenzaThe Lancet, 2001
- A DNA transfection system for generation of influenza A virus from eight plasmidsProceedings of the National Academy of Sciences, 2000
- Elastin Degradation by Matrix MetalloproteinasesJournal of Biological Chemistry, 1997
- Virulence-associated sequence duplication at the hemagglutinin cleavage site of avian influenza virusesVirus Research, 1997
- Trypsin-resistant protease activation mutants of an influenza virusJournal of General Virology, 1995
- Pathogenicity of influenza A/Seal/Mass/1/80 virus mutants for mammalian speciesArchiv für die gesamte Virusforschung, 1995
- Host cell proteases controlling virus pathogenicityTrends in Microbiology, 1994